Search

Your search keyword '"Enterovirus A, Human genetics"' showing total 838 results

Search Constraints

Start Over You searched for: Descriptor "Enterovirus A, Human genetics" Remove constraint Descriptor: "Enterovirus A, Human genetics"
838 results on '"Enterovirus A, Human genetics"'

Search Results

1. Cleavage of Stau2 by 3C protease promotes EV-A71 replication.

2. Tanomastat exerts multi-targeted inhibitory effects on viral capsid dissociation and RNA replication in human enteroviruses.

3. Analysis of miRNAs involved in mouse brain injury upon Coxsackievirus A6 infection.

4. Correlations of PSGL-1 VNTR polymorphism with the susceptibility to severe HFMD associated with EV-71 and the immune status after infection.

5. Changing Epidemiology of Hand, Foot, and Mouth Disease Causative Agents and Contributing Factors.

6. Enterovirus A71 2A-S125A acts as an attenuated vaccine candidate, indicating a universal approach in developing enterovirus vaccines.

7. Design of antiviral AGO2-dependent short hairpin RNAs.

8. AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase.

9. NSUN2 mediates distinct pathways to regulate enterovirus 71 replication.

10. Tribbles pseudokinase 3 promotes enterovirus A71 infection via dual mechanisms.

11. Targeting Ser78 phosphorylation of Hsp27 achieves potent antiviral effects against enterovirus A71 infection.

12. Enterovirus-A71 preferentially infects and replicates in human motor neurons, inducing neurodegeneration by ferroptosis.

13. Molecular Evolutionary Dynamics of Coxsackievirus A6 Causing Hand, Foot, and Mouth Disease From 2021 to 2023 in China: Genomic Epidemiology Study.

14. Single nucleotide polymorphism of Notch1 gene rs3124599 allele is associated with the severity of CVA6-related HFMD in the Chinese Han population.

15. Enterovirus-A71 exploits RAB11 to recruit chaperones for virus morphogenesis.

16. Immunogenicity and immunodominant linear B-cell epitopes of a new DNA-based tetravalent vaccine against four major enteroviruses causing hand, foot, and mouth disease.

17. Enterovirus A71 crosses a human blood-brain barrier model through infected immune cells.

18. Genomic epidemiology of CVA10 in Guangdong, China, 2013-2021.

19. Efficient Production of Enterovirus 71 (EV71) Virus-like Particles by Controlling Promoter Strength in Insect Cells.

20. EV71 5'UTR interacts with 3D protein affecting replication through the AKT-mTOR pathway.

21. The EV71 2A protease occupies the central cleft of SETD3 and disrupts SETD3-actin interaction.

22. Hyperglycemia facilitates EV71 replication: Insights into miR-206-mediated regulation of G3BP2 promoting EV71 IRES activity.

23. Construction of an infectious clone for enterovirus A89 and mutagenesis analysis of viral infection and cell binding.

24. Identification of fangchinoline as a broad-spectrum enterovirus inhibitor through reporter virus based high-content screening.

25. Rapid detection of four major HFMD-associated enteroviruses by multiplex HiFi-LAMP assays.

26. Cordycepin Inhibits Enterovirus A71 Replication and Protects Host Cell from Virus-Induced Cytotoxicity through Adenosine Action Pathway.

27. Enterovirus A71 does not meet the uncoating receptor SCARB2 at the cell surface.

28. Advances in anti-EV-A71 drug development research.

29. VP1 codon deoptimization and high-fidelity substitutions in 3D polymerase as potential vaccine strategies for eliciting immune responses against enterovirus A71.

30. A novel mucosal bivalent vaccine of EV-A71/EV-D68 adjuvanted with polysaccharides from Ganoderma lucidum protects mice against EV-A71 and EV-D68 lethal challenge.

31. Inhibition of lysosome-tethered Ragulator-Rag-3D complex restricts the replication of Enterovirus 71 and Coxsackie A16.

32. Dual carminic acid/hemin-marked DNA probes for simultaneously detecting CV-A16 and EV-A71 based on the mechanism of dimer to monomer transition.

33. Humoral and cellular immunogenicity and efficacy of a coxsackievirus A10 vaccine in mice.

34. Coxsackievirus A6 2C protein antagonizes IFN-β production through MDA5 and RIG-I depletion.

35. Application value of EV/EV71/CA16-SAT detection in children with hand-foot-mouth disease.

36. Molecular epidemiology and phylodynamic analysis of enterovirus 71 in Beijing, China, 2009-2019.

37. An enterovirus A71 virus-like particle with replaced loops confers partial cross-protection in mice.

38. The Upf1 protein restricts EV-A71 viral replication.

39. Neutralization of African enterovirus A71 genogroups by antibodies to canonical genogroups.

40. Identification of Critical Amino Acids of Coxsackievirus A10 Associated with Cell Tropism and Viral RNA Release during Uncoating.

41. Targeting HNRNPA2B1 inhibits enterovirus 71 replication in SK-N-SH cells.

42. Molecular evolutionary dynamics of enterovirus A71, coxsackievirus A16 and coxsackievirus A6 causing hand, foot and mouth disease in Thailand, 2000-2022.

43. VP2 residue N142 of coxsackievirus A10 is critical for the interaction with KREMEN1 receptor and neutralizing antibodies and the pathogenicity in mice.

44. The neuropathological mechanism of EV-A71 infection attributes to inflammatory pryoptosis and viral replication via activating the hsa_circ_0045431/ hsa_miR_584/NLRP3 regulatory axis.

45. Research progress on pathogenic and therapeutic mechanisms of Enterovirus A71.

46. Potential of a bivalent vaccine for broad protection against enterovirus 71 and coxsackie virus 16 infections causing hand, foot, and mouth disease.

47. The effects of SCARB2 and SELPLG gene polymorphisms on EV71 infection in hand, foot and mouth disease.

48. Molecular epidemiology and clinical characteristics of enteroviruses associated HFMD in Chengdu, China, 2013-2022.

49. miR-342-5p targets CTNNBIP1 to promote enterovirus 71 replication.

50. Phylogenetics and phylogeographic characteristics of coxsackievirus A16 in hand foot and mouth disease and herpangina cases collected in Beijing, China from 2019 to 2021.

Catalog

Books, media, physical & digital resources